Q3 Earnings Forecast for Geron Issued By Leerink Partnrs

Key Points

• Leerink Partners projects that Geron Corporation will report earnings per share of ($0.01) for Q3 2026, with a full-year consensus estimate of ($0.25).
• Goldman Sachs initiated coverage of Geron with a sell rating and a price target of $1.00, while Scotiabank downgraded its target from $4.00 to $1.50.
• Geron reported a significant year-over-year revenue increase of 5455.6%, with a quarterly revenue of $49.04 million, surpassing analysts' expectations.

Geron Corporation (NASDAQ:GERN - Free Report) - Research analysts at Leerink Partnrs issued their Q3 2026 earnings per share (EPS) estimates for shares of Geron in a research note issued to investors on Tuesday, August 12th. Leerink Partnrs analyst F. Khurshid expects that the biopharmaceutical company will post earnings of ($0.01) per share for the quarter. The consensus estimate for Geron's current full-year earnings is ($0.25) per share.

A number of other equities analysts also recently issued reports on GERN. Scotiabank downgraded Geron from a "sector outperform" rating to a "sector perform" rating and cut their price target for the company from $4.00 to $1.50 in a research note on Thursday, May 8th. The Goldman Sachs Group initiated coverage on Geron in a research note on Thursday, July 10th. They set a "sell" rating and a $1.00 price target for the company. One analyst has rated the stock with a sell rating, three have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $4.19.

Geron Price Performance

GERN stock remained flat at $1.45 during mid-day trading on Wednesday. The company's stock had a trading volume of 12,194,961 shares, compared to its average volume of 11,930,566. The firm has a market cap of $925.13 million, a PE ratio of -11.15 and a beta of 0.73. The company has a current ratio of 7.87, a quick ratio of 6.79 and a debt-to-equity ratio of 0.46. Geron has a fifty-two week low of $1.09 and a fifty-two week high of $4.83. The company has a fifty day simple moving average of $1.38 and a 200 day simple moving average of $1.61.

Geron (NASDAQ:GERN - Get Free Report) last issued its earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating analysts' consensus estimates of ($0.03) by $0.01. Geron had a negative return on equity of 31.37% and a negative net margin of 53.52%. The business had revenue of $49.04 million during the quarter, compared to analyst estimates of $47.30 million. During the same period in the previous year, the company posted ($0.10) EPS. The firm's revenue was up 5455.6% compared to the same quarter last year.

Hedge Funds Weigh In On Geron

Several institutional investors have recently modified their holdings of GERN. RA Capital Management L.P. grew its holdings in shares of Geron by 101.2% in the first quarter. RA Capital Management L.P. now owns 60,379,366 shares of the biopharmaceutical company's stock valued at $96,003,000 after acquiring an additional 30,369,830 shares in the last quarter. Soleus Capital Management L.P. grew its holdings in shares of Geron by 572.5% in the second quarter. Soleus Capital Management L.P. now owns 16,140,000 shares of the biopharmaceutical company's stock valued at $22,757,000 after acquiring an additional 13,740,000 shares in the last quarter. Vestal Point Capital LP grew its holdings in shares of Geron by 100.0% in the first quarter. Vestal Point Capital LP now owns 22,005,340 shares of the biopharmaceutical company's stock valued at $34,988,000 after acquiring an additional 11,005,340 shares in the last quarter. Braidwell LP bought a new position in shares of Geron in the fourth quarter valued at approximately $24,802,000. Finally, Boxer Capital Management LLC bought a new position in shares of Geron in the fourth quarter valued at approximately $21,240,000. 73.71% of the stock is owned by institutional investors.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.